Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15941659 | 1.00 | PLA2G4A (0.60) | PLA2G4ATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL15887073 | 0.88 | PLA2G4A (0.47) | PLA2G4ATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL17804033 | 0.86 | PLA2G4A (0.48) | PLA2G4ATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL20830129 | 0.84 | CA1 (0.40) | PLA2G4ACYP2D6SMPD1 | |
| SCHEMBL6419171 | 0.82 | MAPT (0.74) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL6410388 | 0.82 | MAPT (0.74) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL6410392 | 0.82 | MAPT (0.74) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL315529 | 0.82 | MAPT (0.74) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL10025150 | 0.82 | MAPT (0.74) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL12451652 | 0.82 | MAPT (0.74) | TP53CYP1A2CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158254-A1 | METHOD FOR PRODUCING N-BOC-SPHINGOSINE AND SPHINGOSINE-1-PHOSPHATE | (주)유케이케미팜 | 2024-08-02 | — | — | WO | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017155923-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | PLA2G4A 1260/4885TP53 693/4885CYP1A2 4521/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | PLA2G4A 1829/4885TP53 994/4885CYP1A2 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.